Comparative Risk of Cancer with non-TNF Advanced Therapies Versus Anti-TNF Therapy in Inflammatory Bowel Disease

BACKGROUND: Safety is important when selecting advanced therapies for inflammatory bowel disease (IBD). Safety data for anti-interleukin therapy (anti-IL) or vedolizumab come from trials with limited follow-up, and direct comparisons with anti-tumor necrosis factors (anti-TNFs) for incident cancer are lacking. We evaluated cancer incidence in patients with IBD treated with anti-IL therapy or vedolizumab versus anti-TNFs. METHODS: We conducted a retrospective cohort study of adults with IBD and no prior cancer who initiated anti-IL therapy, vedolizumab or anti-TNFs. Our primary outcome was incident cancer from 90 days after therapy initiation through discontinuation. We calculated incidence rates and performed Cox proportional hazards models. RESULTS: We identified 4,019 advanced therapy starts: 995 anti-IL, 692 vedolizumab, and 2,332 anti-TNF starts, with mean therapy duration of 1096 days. In multivariable analysis, there was a trend towards a lower hazard of all cancers among anti-IL users compared to anti-TNF users (HR 0.47; 95% CI 0.21-1.04), which was significant on sensitivity analyses. There was no difference in hazard of skin cancers (HR 1.56; 95% CI 0.39-6.15); however, the hazard of non-skin cancer was significantly lower among anti-IL users compared to anti-TNF users (HR 0.28; 95% CI 0.09-0.81). When comparing vedolizumab to anti-TNFs, there was no significant difference in the hazard of all cancer (HR 0.52, 95% CI 0.24-1.12) and non-skin cancer (HR 0.63, 95% CI 0.29-1.39). CONCLUSIONS: We found no evidence of an increased cancer risk with anti-IL therapy compared with anti-TNF therapy in patients with IBD. There was no difference in the cancer risk between vedolizumab and anti-TNF therapy.

Authors

Institutions

Publication Details

Journal
The American Journal of Gastroenterology
Published
2026-11-12
DOI
https://doi.org/10.14309/ajg.0000000000004251
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Comparative Risk of Cancer with non-TNF Advanced Therapies Versus Anti-TNF Therapy in Inflammatory Bowel Disease

Sama Anvari, Maryam K. Ibrahim, Isita Tripathi, Ashwin N. Ananthakrishnan et al.
The American Journal of Gastroenterology
Inflammatory Bowel Disease
article

Comparative Risk of Cancer with non-TNF Advanced Therapies Versus Anti-TNF Therapy in Inflammatory Bowel Disease

Sama Anvari, Maryam K. Ibrahim, Isita Tripathi, Ashwin N. Ananthakrishnan, Tianxi Cai, Wasuwit Wanchaitanawong, Xin Xiong
article en

Abstract

BACKGROUND: Safety is important when selecting advanced therapies for inflammatory bowel disease (IBD). Safety data for anti-interleukin therapy (anti-IL) or vedolizumab come from trials with limited follow-up, and direct comparisons with anti-tumor necrosis factors (anti-TNFs) for incident cancer are lacking. We evaluated cancer incidence in patients with IBD treated with anti-IL therapy or vedolizumab versus anti-TNFs. METHODS: We conducted a retrospective cohort study of adults with IBD and no prior cancer who initiated anti-IL therapy, vedolizumab or anti-TNFs. Our primary outcome was incident cancer from 90 days after therapy initiation through discontinuation. We calculated incidence rates and performed Cox proportional hazards models. RESULTS: We identified 4,019 advanced therapy starts: 995 anti-IL, 692 vedolizumab, and 2,332 anti-TNF starts, with mean therapy duration of 1096 days. In multivariable analysis, there was a trend towards a lower hazard of all cancers among anti-IL users compared to anti-TNF users (HR 0.47; 95% CI 0.21-1.04), which was significant on sensitivity analyses. There was no difference in hazard of skin cancers (HR 1.56; 95% CI 0.39-6.15); however, the hazard of non-skin cancer was significantly lower among anti-IL users compared to anti-TNF users (HR 0.28; 95% CI 0.09-0.81). When comparing vedolizumab to anti-TNFs, there was no significant difference in the hazard of all cancer (HR 0.52, 95% CI 0.24-1.12) and non-skin cancer (HR 0.63, 95% CI 0.29-1.39). CONCLUSIONS: We found no evidence of an increased cancer risk with anti-IL therapy compared with anti-TNF therapy in patients with IBD. There was no difference in the cancer risk between vedolizumab and anti-TNF therapy.

The American Journal of Gastroenterology
Harvard University (US), Massachusetts General Hospital (US), Chiang Mai University (TH)
Good health and well-being
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon